Analysts Set DexCom, Inc. (NASDAQ:DXCM) Target Price at $85.00

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given an average rating of “Moderate Buy” by the twenty-five analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, seventeen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $85.2727.

Several brokerages have recently weighed in on DXCM. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Stifel Nicolaus initiated coverage on shares of DexCom in a research note on Tuesday, October 21st. They issued a “buy” rating and a $85.00 price target on the stock. Truist Financial restated a “buy” rating and set a $82.00 price objective (down from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th. Finally, Mizuho upped their target price on shares of DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $70.02 on Thursday. The company has a 50 day simple moving average of $69.03 and a two-hundred day simple moving average of $69.60. DexCom has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The company has a market capitalization of $27.31 billion, a price-to-earnings ratio of 33.34, a P/E/G ratio of 1.25 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.84% and a net margin of 17.94%.The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same period in the previous year, the firm posted $0.45 EPS. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. Analysts expect that DexCom will post 2.03 EPS for the current fiscal year.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Andra AP fonden purchased a new position in DexCom in the 2nd quarter worth about $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in shares of DexCom during the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. lifted its position in DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new position in DexCom during the third quarter valued at approximately $29,000. Finally, CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.